Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Clinical trial NCT05385263 · UNKNOWN

Trial details

NCT number: NCT05385263
Sponsor: Tel-Aviv Sourasky Medical Center
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

B Cell Lymphoma

Start date: 2022-05-11
Primary completion: 2024-04-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.